SJEPD025_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 2.51
- e1_e2
- E2
- umap1_2d
- -5.871449977
- umap2_2d
- -0.993198633
- umap1_3d
- 1.276843271
- umap2_3d
- 2.510096061
- umap3_3d
- 0.906356258
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.440
- KRAS_SIGNALING_DN+0.320
- XENOBIOTIC_METABOLISM+0.320
- COAGULATION+0.300
- TNFA_SIGNALING_VIA_NFKB+0.290
- ADIPOGENESIS+0.280
- FATTY_ACID_METABOLISM+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- UV_RESPONSE_UP+0.270
- BILE_ACID_METABOLISM+0.260
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.590
- MYC_TARGETS_V1-0.520
- MITOTIC_SPINDLE-0.380
- PROTEIN_SECRETION-0.320
- MYC_TARGETS_V2-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.260
- MTORC1_SIGNALING-0.240
- DNA_REPAIR-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001515_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.853 |
| 2 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.837 |
| 3 | BS_CVGFNCBJ | low-grade glioma | — | 0.835 |
| 4 | BS_34201DKZ | Spinal Cord Ependymoma | — | 0.825 |
| 5 | SRR1341521 | GTEX | — | 0.823 |
| 6 | SRR5903552 | — | cohortA1 | 0.820 |
| 7 | BS_34201DKZ | EPN | EPN Tumor | 0.817 |
| 8 | SRR4296108 | — | cohortA1 | 0.809 |
| 9 | TCGA-MP-A4T7-01A-11R-A24X-07 | — | cohortA4 | 0.801 |
| 10 | BS_X0F9AYEC | pilocytic astrocytoma | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |